CSIMarket
 
Pieris Pharmaceuticals Inc   (PIRS)
Other Ticker:  
 
 
Price: $0.1690 $0.00 -1.170%
Day's High: $0.1772 Week Perf: -0.59 %
Day's Low: $ 0.16 30 Day Perf: 9.03 %
Volume (M): 346 52 Wk High: $ 1.52
Volume (M$): $ 59 52 Wk Avg: $0.40
Open: $0.17 52 Wk Low: $0.14



 Market Capitalization (Millions $) 17
 Shares Outstanding (Millions) 99
 Employees -
 Revenues (TTM) (Millions $) 47
 Net Income (TTM) (Millions $) -28
 Cash Flow (TTM) (Millions $) -16
 Capital Exp. (TTM) (Millions $) 0

Pieris Pharmaceuticals Inc
Pieris Pharmaceuticals Inc. is a biotechnology company based in the United States. The company focuses on the discovery and development of Anticalin-based drugs, which are therapeutic proteins derived from lipocalins, a type of human protein. Pieris Pharmaceuticals' drugs are designed to target specific diseases and bind to disease-causing proteins, offering potential treatments for a range of conditions including cancer, respiratory diseases, and metabolic disorders. The company aims to leverage its proprietary Anticalin platform to develop innovative therapies that address unmet medical needs.


   Company Address: 225 Franklin Street, 26th Floor Boston 2110 MA
   Company Phone Number: 246-8998   Stock Exchange / Ticker: NASDAQ PIRS
   PIRS is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc Soars to New Heights with Impressive Revenue Growth



Pieris Pharmaceuticals Inc, a pharmaceutical company listed on the NASDAQ, has witnessed a decline of -8.45% in its stock value over the past seven days, resulting in a year-to-date performance of -77.83%. However, the company's latest financial results reveal robust revenue growth, increasing by 263.501% year on year to $19.52 million in the financial period ending on September 30, 2023. Despite this positive development, Pieris Pharmaceuticals Inc reported a net loss of $-0.11 per share for the same period. It is essential to analyze these results and consider their implications for the company's future prospects.
1. Strong Revenue Growth:
Pieris Pharmaceuticals Inc achieved a remarkable revenue increase of 263.501% compared to the previous year. This growth outperformed the Major Pharmaceutical Preparations industry, which experienced a 4.82% reduction in revenue during the same financial reporting period. The significant boost in revenue demonstrates the company's ability to attract customers and capitalize on market demand.

Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc Sees Revenue Surge as EPS Declines in April-June 2023 Quarter

Despite Pieris Pharmaceuticals Inc's impressive revenue growth of 442.32% year on year, there are several concerning factors that suggest a bearish outlook for the company. While the company was able to achieve a positive EPS of $0.05 in the second quarter of 2023, this positive turnaround in earnings is unexpected given the drastic contraction of -9.44% in the Major Pharmaceutical Preparations industry.
Although Pieris Pharmaceuticals Inc's revenue doubled by 935.899% from $1.94 million to $20.06 million in the second quarter, it is important to note that this growth is relative to the preceding quarter and doesn't necessarily reflect long-term sustainability. Furthermore, the company's net margin increased to 19.83% and operating margin rose to 10.29%. While these improvements in profit margins may seem positive, the decline in accounts receivable to $1.0 million could indicate slowing demand for the company's products.

Pieris Pharmaceuticals Inc

Pieris Pharmaceuticals Inc Faces Significant Losses, Struggles to Generate Profits in Recent Fiscal Period

Pieris Pharmaceuticals Inc, a Major Pharmaceutical Preparations company, has recorded a cumulative net loss of $-41 million during the 12 months ending in the first quarter of 2023. This has resulted in a negative return on equity (ROE) of -133.94%. This is concerning news for investors, as it indicates that the company is not generating any profits and is losing money.
Furthermore, within the Major Pharmaceutical Preparations industry, 217 other companies had a higher return on equity than Pieris Pharmaceuticals Inc. This means that Pieris Pharmaceuticals Inc is falling behind its competitors in terms of generating profits.






 

Pieris Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com